CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY – Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 74 shares, a decrease of 99.5% from the August 31st total of 15,269 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 48,753 shares, the days-to-cover ratio is currently 0.0 days.
Analysts Set New Price Targets
Several brokerages have recently weighed in on CHEOY. Canaccord Genuity Group downgraded CochLear from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 18th. Zacks Research upgraded CochLear from a “strong sell” rating to a “hold” rating in a report on Monday, June 22nd. Royal Bank Of Canada downgraded CochLear from an “outperform” rating to a “sector perform” rating and set a $117.00 price objective on the stock. in a research report on Thursday, July 16th. Finally, Jefferies Financial Group lowered CochLear from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Five analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $117.00.
Get Our Latest Stock Report on CochLear
CochLear Trading Up 1.5%
About CochLear
Cochlear Limited is an Australian medical device company that develops, manufactures and supplies implantable hearing solutions. Its products are designed for people with severe to profound hearing loss who may not receive sufficient benefit from conventional hearing aids.
The company’s portfolio includes cochlear implants, bone conduction hearing implants, and related sound processors, accessories, software and support services. Cochlear also provides rehabilitation resources, clinical support and ongoing product services intended to help recipients use and maintain their hearing systems.
Founded in 1981 and headquartered in Sydney, Australia, Cochlear serves customers through a global network spanning Australia, New Zealand, North America, Europe, Asia and other international markets.
Featured Stories
- Five stocks we like better than CochLear
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for CochLear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CochLear and related companies with MarketBeat.com's FREE daily email newsletter.
